- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04152161
Bacille Calmette Guerin (BCG) Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained Infection
October 4, 2023 updated by: Bill & Melinda Gates Medical Research Institute
A Randomized, Placebo Controlled, Observer-Blind, Phase IIb Study to Evaluate the Efficacy, Safety, and Immunogenicity of BCG Revaccination in Healthy Adolescents for the Prevention of Sustained Infection With Mycobacterium Tuberculosis
The purpose of this study is to demonstrate the efficacy of Bacille Calmette Guerin (BCG) revaccination against sustained Mycobacterium tuberculosis infection versus placebo in previously BCG vaccinated QuantiFERON®-TB Gold Plus Assay (QFT) negative, healthy adolescents.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
1836
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Cape Town
-
Klipfontein, Cape Town, South Africa, 7750
- Investigational Site
-
-
Durban
-
Berea, Durban, South Africa, 4001
- Investigational Site
-
-
Johannesburg
-
Hillbrow, Johannesburg, South Africa, 2001
- Investigational Site
-
-
Western Cape
-
Paarl, Western Cape, South Africa, 7626
- Investigational Site
-
Worcester, Western Cape, South Africa, 6850
- Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Participant between ≥ 10 years and ≤ 18 years on Study Day 1
- General good health, confirmed by medical history and physical examination
- Vaccinated with Bacille Calmette Guerin (BCG) at least 5 years ago, documented through medical history or by presence of healed BCG scar
- Tests QuantiFERON®-TB Gold Plus Assay (QFT) negative at screening.
- For female participants: not pregnant and agrees to avoid pregnancy throughout the first 12 months of the study. Women physically capable of pregnancy must agree to use an acceptable method of avoiding pregnancy during this period. Acceptable methods of avoiding pregnancy include sexual abstinence (not engaging in sexual intercourse), a confirmed sterile partner, or at least 2 contraception methods from the following list: male or female condom, diaphragm, intrauterine devices (IUDs), hormonal contraceptive (oral, injection, transdermal patch, or implant).
- Agrees to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study
- Capable of giving signed informed consent/assent and completes the written informed consent/assent process.
Exclusion Criteria:
- Acute illness on Study Day 1. NOTE: This is a temporary exclusion for which the participant may be re-evaluated
- Body temperature ≥37.5 degree Celsius on Study Day 1. NOTE: This is a temporary exclusion for which the participant may be re-evaluated
- History or evidence of any clinically significant disease, including severe eczema and severe asthma, or any acute or chronic illness that might affect the safety, immunogenicity, or efficacy of study vaccine in the opinion of the investigator
- Any current medical, psychiatric, occupational, or substance abuse problems that, in the opinion of the investigator, will make it unlikely that the participant will comply with the protocol
- History of autoimmune disease
- History or evidence of active tuberculosis (TB) disease
- History or laboratory evidence of any past or present possible immunodeficiency state including, but not limited to, any laboratory indication of human immunodeficiency virus - 1 (HIV-1) infection
- History of allergic disease that is likely to be exacerbated by any component of the study vaccine
- History of treatment for active TB disease or history of latent Mycobacterium tuberculosis infection
- Received a tuberculin skin test within 6 months prior to Study Day 1
- Received immunosuppressive treatment, e.g., chemotherapy, biologics or radiation therapy, or used immunosuppressive medication (daily steroid equivalent of ≥5 milligrams prednisone) within 42 days before Study Day 1. Inhaled and topical corticosteroids are permitted.
- Received immunoglobulin or blood products within 42 days before Study Day 1
- Planned administration/administration of a licensed vaccine in the period starting 28 days before and ending 28 days after Study Day 1
- Received investigational TB vaccine at any time prior to Study Day 1
- Received any investigational drug therapy or investigational vaccine within 180 days before Study Day 1, or planned participation in any other clinical trial using investigational product during the study period
- Laboratory values from the most recent blood collected prior to randomization outside the normal range that are suggestive of a disease state. Grade 1 abnormalities (as per Division of Acquired Immunodeficiency Syndrome toxicity table version 2.1) do not lead to exclusion if the investigator considers them not clinically significant
- Urinalysis abnormality greater than Grade 1 on the Toxicity Scale (with the exception of hematuria in a menstruating female), or urinalysis abnormality judged clinically significant by the investigator
- Shared residence with an individual who is receiving TB treatment or with someone who is known to have incompletely treated TB. e.g., Xpert Mycobacterium tuberculosis (MTB)/rifampicin (RIF) assay-positive, polymerase chain reaction-positive, culture-positive, smear-positive TB, or clinically diagnosed unconfirmed TB
- Child in Care
- Female participants currently pregnant or lactating/nursing; or positive serum pregnancy test during screening or on Day 1, prior to vaccination, or planning a pregnancy within the first 12 months after study intervention
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo group
|
Participants will receive a single 0.1 mL volume of normal saline, administered intradermally in deltoid region of the upper arm.
|
Experimental: Bacille Calmette Guerin (BCG) group
|
Participants will receive a single 0.1 milliliter (mL) volume of BCG vaccine SSI, administered intradermally in deltoid region of the upper arm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Sustained QuantiFERON®-TB Gold Plus Assay (QFT) Conversion From a Negative to Positive Test Based on positive QFT test results
Time Frame: Up to 48 months
|
Sustained Conversion means initial conversion and QFT Positive 3 and 6 months later.
|
Up to 48 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants With Solicited Adverse Events (AEs)
Time Frame: Day 1 through 7 days post vaccination
|
Day 1 through 7 days post vaccination
|
Number of Participants With Unsolicited AEs
Time Frame: Day 1 through 28 days post vaccination
|
Day 1 through 28 days post vaccination
|
Number of Participants With Serious Adverse Events
Time Frame: Day 1 through Month 6
|
Day 1 through Month 6
|
Number of Participants With AEs of Special Interest
Time Frame: Day 1 through Month 6
|
Day 1 through Month 6
|
Number of Participants With Serious Adverse Drug Reactions
Time Frame: Day 1 through end of study participation i.e. approximately 48 months
|
Day 1 through end of study participation i.e. approximately 48 months
|
Number of Participants with Sustained QFT Conversion From a Negative to Positive Test Based on positive QFT test results
Time Frame: Initial conversion and QFT-positive at 3- and 6-months post conversion, with a minimum follow-up of 36- and 48-months post vaccination
|
Initial conversion and QFT-positive at 3- and 6-months post conversion, with a minimum follow-up of 36- and 48-months post vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Gates MRI, Bill & Melinda Gates Medical Research Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 16, 2019
Primary Completion (Estimated)
September 1, 2025
Study Completion (Estimated)
September 1, 2025
Study Registration Dates
First Submitted
October 22, 2019
First Submitted That Met QC Criteria
November 1, 2019
First Posted (Actual)
November 5, 2019
Study Record Updates
Last Update Posted (Actual)
October 5, 2023
Last Update Submitted That Met QC Criteria
October 4, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Gates MRI-TBV01-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Assistance Publique - Hôpitaux de ParisCompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone TuberculosisFrance
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University Medical Center GroningenCompletedMultidrug-resistant Tuberculosis | Extensively Drug-resistant TuberculosisNetherlands
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
National Institute of Allergy and Infectious Diseases...CompletedPulmonary Tuberculosis | Multidrug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisKorea, Republic of
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... and other collaboratorsActive, not recruitingTuberculosis | Multi Drug Resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Extensively Drug-Resistant Tuberculosis | Pre-XDR-TBSouth Africa
Clinical Trials on BCG vaccine SSI
-
Lone Graff StensballeHvidovre University Hospital; Kolding Sygehus; Danish National Research Foundation and other collaboratorsCompletedProspective | Single-blind | Clinical | Trial | InterventionDenmark
-
Radboud University Medical CenterCompletedInnate Immune Response
-
University of OxfordUniversity of Birmingham; AerasCompleted
-
Radboud University Medical CenterCompleted
-
AerasSanofi Pasteur, a Sanofi CompanyCompleted
-
Mark HatherillMedical Research Council; University of Oxford; Wellcome Trust; Department for... and other collaboratorsCompletedSafety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination (MVA(TB)029)HIV | TuberculosisSouth Africa
-
Radboud University Medical CenterUniversity of Southern DenmarkUnknown
-
Bandim Health ProjectUniversity of Southern DenmarkRecruitingMorbidity;Newborn | Non-specific Effects of Vaccines | Death, Infant | Morbidity;Infant | Death; NeonatalGuinea-Bissau
-
Bandim Health ProjectOdense University Hospital; Odense Patient Data Explorative Network; Municipality...CompletedCovid19 | Immunosenescence | Vaccine Preventable Disease | Morbidity | Non-specific Effects of Vaccines | Heterologous ImmunityDenmark
-
Radboud University Medical CenterActive, not recruitingEpigenetics | Trained Immunity | BCG VaccineNetherlands